We apologize for Proteopedia being slow to respond. For the past two years, a new implementation of Proteopedia has been being built. Soon, it will replace this 18-year old system. All existing content will be moved to the new system at a date that will be announced here.
User:Elizabeth Yowell/ SandboxFinal
From Proteopedia
(Difference between revisions)
| Line 7: | Line 7: | ||
The enzyme angiotensin converting enzyme 2 (ACE2) is attached to our cell membranes and then can be bound to a receptor binding domain (RBD) <ref name="Borkotoky">DOI:10.1007/s11033-022-08193-4</ref>. The spike protein of SARS-CoV-2 enters our bodies and binds to the RBD, allowing the spike protein access to ACE2 and our host cells <ref name=”Jackson”>DOI:10.1038/s41580-021-00418-x</ref>. Once the spike protein has access to our host cells, it is able to further infect our cells and spread the virus throughout our bodies, causing us to get sick. In order to create an effective vaccine, the pathway between the spike protein and the RBD needed to be [https://www.sciencedirect.com/science/article/pii/S0166354223000190 interrupted]. | The enzyme angiotensin converting enzyme 2 (ACE2) is attached to our cell membranes and then can be bound to a receptor binding domain (RBD) <ref name="Borkotoky">DOI:10.1007/s11033-022-08193-4</ref>. The spike protein of SARS-CoV-2 enters our bodies and binds to the RBD, allowing the spike protein access to ACE2 and our host cells <ref name=”Jackson”>DOI:10.1038/s41580-021-00418-x</ref>. Once the spike protein has access to our host cells, it is able to further infect our cells and spread the virus throughout our bodies, causing us to get sick. In order to create an effective vaccine, the pathway between the spike protein and the RBD needed to be [https://www.sciencedirect.com/science/article/pii/S0166354223000190 interrupted]. | ||
| + | |||
| + | ==Vaccines== | ||
| + | <scene name='10/1076049/Antibody_overview/1'>Antibody Overview</scene> | ||
| + | <scene name='10/1076049/Antibody/5'>Antibody Binding Site</scene> | ||
| + | |||
| + | ==Mechanism== | ||
| + | |||
| + | ==Binding Site== | ||
| + | |||
| + | ==Inhibitor Differences== | ||
| + | |||
| + | </StructureSection> | ||
| + | |||
| + | ==References== | ||
| + | |||
| + | ===PDB Files=== | ||
| + | [1]https://www.rcsb.org/structure/7UHB | ||
| + | |||
| + | ==Student Contributors== | ||
| + | *Giavanna Yowell | ||
| + | *Shea Bailey | ||
| + | *Matthew Pereira | ||
Revision as of 20:12, 2 April 2025
Contents |
SARS CoV-2 Protein Inhibitors (AHB2 and LCB1/LCB3)
| |||||||||||
References
PDB Files
[1]https://www.rcsb.org/structure/7UHB
Student Contributors
- Giavanna Yowell
- Shea Bailey
- Matthew Pereira
